Pilot Study of Duloxetine in Adult Attention Deficit Hyperactivity Disorder(ADHD)
NCT ID: NCT00940693
Last Updated: 2010-12-14
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
40 participants
INTERVENTIONAL
2009-08-31
2010-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
duloxetine
duloxetine
60 mg capsule once per day for 6 weeks
placebo
placebo
one capsule of placebo taken one a day for 6 weeks
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
duloxetine
60 mg capsule once per day for 6 weeks
placebo
one capsule of placebo taken one a day for 6 weeks
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Able to give consent
* Able to swallow capsules
Exclusion Criteria
* Under psychotherapy for ADHD
* Taking a medication that interacts with duloxetine, including all psychotropic medication
* Treated with medication for ADHD
* Unstable medical condition
* Severe renal insufficiency
* Liver insufficiency
* Substance/alcool abuse or dependency in the last 6 months
* Pregnancy, nursing or inadequate contraceptive methods
* Suicide or homicide risk
* Organic brain syndrome
* Any diagnosis of lifetime bipolar disorder or psychotic disorder, and any actual diagnosis of anxious disorder or major depressive disorder
18 Years
50 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Centre hospitalier de l'Université de Montréal (CHUM)
OTHER
Université de Montréal
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Centre Hospitalier Universitaire de Montréal
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Valérie Tourjman, MD
Role: PRINCIPAL_INVESTIGATOR
Centre hospitalier de l'Université de Montréal (CHUM)
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Centre Hospitalier Universitaire de Montréal: Hôpital Notre-Dame
Montreal, Quebec, Canada
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Tourjman SV, Bilodeau M. Improvement with duloxetine in an adult ADHD patient. J Atten Disord. 2009 Jul;13(1):95-6. doi: 10.1177/1087054708326109. Epub 2009 Apr 9.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
09.008
Identifier Type: -
Identifier Source: org_study_id